Global Glaucoma Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Glaucoma Therapeutics Market Growth (Status and Outlook) 2023-2029

Glaucoma is chronic, degenerative disorder that damages the eye's optic nerve, may result in vision loss and blindness. Factors such, high prevalence of glaucoma, technological advancement in diagnostic technique, rising treatment awareness are driving the market growth of glaucoma therapeutics globally.

LPI (LP Information)' newest research report, the “Glaucoma Therapeutics Industry Forecast” looks at past sales and reviews total world Glaucoma Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Glaucoma Therapeutics sales for 2023 through 2029. With Glaucoma Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glaucoma Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Glaucoma Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glaucoma Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Glaucoma Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glaucoma Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glaucoma Therapeutics.

The global Glaucoma Therapeutics market size is projected to grow from US$ 5554.4 million in 2022 to US$ 7859 million in 2029; it is expected to grow at a CAGR of 5.1% from 2023 to 2029.

The change in the lifestyle of people has resulted in the rise in the prevalence of glaucoma globally. Increasing prevalence of glaucoma is the primary factor driving the growth of glaucoma therapeutics market around the globe. Glaucoma is more prevalent among the people above the age of 60. Rising geriatric population thought the globe is also responsible for the robust growth of glaucoma therapeutics market over the forecast period. Increasing preference of physician towards the laser surgery for the treatment of glaucoma will propel the growth of glaucoma therapeutics market over the forecast period. Less awareness among the people about the glaucoma treatment will deter the growth of glaucoma therapeutics market to some extent. Moreover, lack of availability of skilled professional for laser surgery in under developing economies will also hamper the growth of glaucoma therapeutics market.

This report presents a comprehensive overview, market shares, and growth opportunities of Glaucoma Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Prostaglandin Analogs
Beta Blockers
Alpha Agonists
Carbonic Anhydrase Inhibitors

Segmentation by application
Ophthalmic Clinic
Hospitals
Ambulatory Surgical Centers

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Pfizer
Novartis
Merck

Please note: The report will take approximately 2 business days to prepare and deliver.